Core Viewpoint - Pagaya Technologies Ltd. (PGY) is expected to report strong third-quarter earnings, with revenues projected to increase significantly year-over-year, driven by growth in fee revenues and network volume [2][9]. Financial Performance - In Q2, PGY achieved total revenues and other income of $326 million, marking a 30% year-over-year increase, primarily due to higher fee revenues [2]. - The Zacks Consensus Estimate for Q3 revenues is $339 million, indicating a 31.9% year-over-year improvement [2][7]. - The earnings estimate for the upcoming quarter remains unchanged at 62 cents per share, reflecting a 40.9% growth from the same quarter last year [3][4]. Estimate Revision Trend - The earnings estimates for the current quarter have remained stable over the past 30 days, with no changes noted [4]. - The consensus estimate for network volume is $2.84 billion, which represents a 20.7% increase from the prior year [8]. Growth Strategy - Pagaya's growth strategy includes expanding product offerings, enhancing monetization of existing partnerships, and adding new enterprise lending partners, particularly large U.S. banks and auto captives [9][20]. - The company anticipates total revenues and other income for Q3 to be between $330 million and $350 million [9]. Valuation and Market Performance - PGY shares have outperformed the S&P 500 Index in Q3 but are considered expensive relative to the industry, with a trailing 12-month price/book (P/B) ratio of 4.19X compared to the industry average of 3.35X [13][16]. - While PGY trades at a premium to LendingClub, it is at a discount to LendingTree, which has a P/B of 5.97X [19]. Business Model Resilience - The company has diversified its business model beyond personal loans into auto lending and point-of-sale financing, which helps mitigate cyclical risks [20]. - Pagaya has established a network of over 135 institutional funding partners to support its asset-backed securities, enhancing liquidity and stability [21].

Core Viewpoint - FS KKR Capital (FSK) is expected to report a quarterly earnings per share (EPS) of $0.57, reflecting a 23% decline year-over-year, with revenues projected at $376.07 million, a decrease of 14.7% compared to the previous year [1]. Earnings Estimates - The consensus EPS estimate has been revised upward by 0.4% in the last 30 days, indicating a reassessment by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock performance [3]. Key Metrics Forecast - Analysts predict 'Investment income- Fee income' to be $9.82 million, down 53.2% year-over-year [5]. - The estimate for 'Investment income- Dividend and other income' is $74.61 million, indicating a 16.6% increase from the previous year [5]. - 'Investment income- Paid-in-kind interest income' is expected to reach $49.79 million, reflecting a 24.6% decline year-over-year [5]. - 'Investment income- Interest income' is forecasted at $239.33 million, down 17.5% from the prior-year quarter [6]. Stock Performance - Over the past month, FS KKR Capital shares have returned -1.6%, while the Zacks S&P 500 composite has increased by 2.1% [6]. - Currently, FS KKR Capital holds a Zacks Rank 4 (Sell), suggesting potential underperformance relative to the overall market in the near future [6].

Core Insights - Verizon Communications Inc. reported strong third-quarter 2025 results with wireless service revenues of $21 billion, reflecting a year-over-year increase of 2.1% [1][4] - Adjusted earnings surpassed the Zacks Consensus Estimate, while total revenues fell short of expectations [1][4] Financial Performance - Net income for the quarter was $5.06 billion, or $1.17 per share, compared to $3.41 billion, or 78 cents per share, in the same quarter last year, driven by top-line growth and reduced operating expenses [3] - Total operating revenues increased by 1.5% to $33.82 billion, but missed the consensus estimate of $34.18 billion [4] - Adjusted earnings were $1.21 per share, slightly above the previous year's $1.19 per share [3] Segment Results - Consumer segment revenues rose by 2.9% year over year to $26.1 billion, exceeding estimates [5] - Business segment revenues declined by 2.8% to $7.14 billion due to lower wholesale and enterprise revenues, falling short of estimates [8] Subscriber Growth - Fixed wireless access net additions reached 261,000, bringing the total subscriber base to nearly 5.4 million, with a target of 8 to 9 million by 2028 [2] - Wireless retail postpaid churn was recorded at 1.12%, while retail postpaid phone churn was 0.91% [6] Operating Metrics - Operating income improved by 36.8% to $8.1 billion, with total operating expenses down by 6.2% to $25.72 billion [11] - Consolidated adjusted EBITDA increased to $12.77 billion, reflecting growth in wireless service revenue [11] Cash Flow and Guidance - Verizon generated $28 billion in net cash from operating activities for the first nine months of 2025, compared to $26.48 billion in the previous year [12] - For 2025, the company anticipates wireless service revenue growth of 2%-2.8% and adjusted EBITDA growth of 2.5%-3.5% [13]

Core Viewpoint - MercadoLibre (MELI) is expected to report quarterly earnings of $9.74 per share, a 24.4% increase year-over-year, with revenues projected at $7.19 billion, reflecting a 35.4% year-over-year growth [1]. Earnings Estimates - Over the past 30 days, the consensus EPS estimate has been adjusted downward by 2.5%, indicating a reassessment by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions to the stock [3]. Revenue Projections - Analysts project 'Revenues- Fintech' at $3.22 billion, a 48.1% increase from the prior year [5]. - 'Revenues- Commerce' is expected to reach $4.08 billion, indicating a 30% year-over-year change [5]. - 'Geographic Revenue- Mexico' is estimated at $1.67 billion, reflecting a 45.7% increase [5]. - 'Geographic Revenue- Argentina' is forecasted to be $1.56 billion, a 51.5% increase [6]. - 'Geographic Revenue- Brazil' is projected at $3.92 billion, showing a 34.5% increase [6]. - 'Geographic Revenue- Fintech- Brazil' is expected to reach $1.50 billion, a 36.3% increase [7]. - 'Geographic Revenue- Other countries' is estimated at $293.12 million, reflecting a 32.6% increase [7]. - 'Geographic Revenue- Fintech- Argentina' is projected at $1.06 billion, indicating a 70.2% increase [8]. - 'Gross merchandise volume' is expected to be $16.20 billion, compared to $12.91 billion in the same quarter last year [9]. - 'Total payment volume' is projected to reach $71.07 billion, up from $50.69 billion year-over-year [9]. Stock Performance - Over the past month, MercadoLibre shares have declined by 13.8%, while the Zacks S&P 500 composite has increased by 1.3% [9].

Core Insights - WaFd, Inc. (WAFD) reported a fourth-quarter fiscal 2025 earnings per share of 72 cents, missing the Zacks Consensus Estimate of 75 cents, but reflecting a year-over-year increase of 1.4% [1][10] - The company's full-year earnings per share of $2.63 also fell short of the Zacks Consensus Estimate of $2.73, although it grew 5.2% year over year [3] Financial Performance - Quarterly net income available to common shareholders was $56.9 million, down 1% from the prior-year quarter, slightly above the estimate of $56.8 million [2] - Full-year net income available to common shareholders was $211.4 million, up 14% from the previous year, closely aligning with the estimate of $211.3 million [3] - Quarterly net revenues were $188.3 million, a slight decline from the prior-year quarter and missing the Zacks Consensus Estimate of $190.2 million [4] - Full-year net revenues totaled $725.5 million, a marginal increase from the previous year, but also missing the Zacks Consensus Estimate of $727.4 million [4] Interest Income and Expenses - Net interest income (NII) for the quarter was $169.9 million, down 1.7% year over year, while the net interest margin (NIM) increased by 9 basis points to 2.71% [5] - Total non-interest income rose 15.8% year over year to $18.4 million, exceeding the estimate of $18 million [5] - Total non-interest expenses were $107 million, a 1% decrease year over year, attributed to lower FDIC insurance premiums and other expenses [6] Asset Quality and Loans - As of September 30, 2025, net loans receivable were $20.09 billion, down 1% from the prior quarter, while total customer deposits increased marginally to $21.44 billion [8] - The allowance for credit losses was 1.04% of gross loans outstanding, up from 1.01% in the prior-year quarter, indicating a deterioration in credit quality [11] Share Repurchase Activity - In the reported quarter, WAFD repurchased 0.97 million shares at an average price of $29.74 per share [12] Market Position and Outlook - The company is expected to benefit from relatively higher interest rates and a solid balance sheet, although it faces challenges from a tough macroeconomic environment [13]

Core Viewpoint - Analysts forecast Abbott (ABT) to report quarterly earnings of $1.30 per share, reflecting a year-over-year increase of 7.4%, with anticipated revenues of $11.41 billion, marking a 7.3% increase compared to the previous year [1]. Earnings Estimates - The consensus EPS estimate has been adjusted downward by 0.1% over the past 30 days, indicating a reassessment by covering analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock performance [3]. Key Metrics Projections - Analysts estimate 'Net sales- Nutrition' to reach $2.20 billion, a year-over-year change of +6.3% [5]. - 'Net sales- Medical Devices- Diabetes Care' is projected at $2.04 billion, indicating an increase of +18.2% year over year [5]. - 'Net sales- Diagnostics' is expected to be $2.31 billion, reflecting a decrease of -4.4% from the previous year [5]. - 'Net sales- Established Pharmaceuticals' is estimated at $1.53 billion, showing a +9% change year over year [6]. - 'Net sales- Diagnostics- U.S.' is projected at $909.57 million, indicating a decline of -11.9% from the prior year [6]. - 'Geographic Revenue- U.S.' is expected to be $4.38 billion, with a year-over-year change of +4.3% [6]. - 'Geographic Revenue- International' is estimated at $7.02 billion, reflecting a +9.2% change year over year [7]. - 'Net sales- Nutrition- International' is projected to reach $1.23 billion, indicating a +9.8% change [7]. - 'Net sales- Nutrition- U.S.' is expected at $966.71 million, reflecting a +1.8% change [7]. - 'Net sales- Diagnostics- International' is forecasted at $1.40 billion, indicating a +1.3% change [8]. - 'Net sales- Medical Devices- Rhythm Management- U.S.' is projected at $325.63 million, reflecting a +13.1% change year over year [8]. - 'Net sales- Medical Devices- Rhythm Management- International' is expected to reach $339.38 million, indicating a +9.8% change year over year [9]. Stock Performance - Abbott shares have returned +0.5% over the past month, compared to the Zacks S&P 500 composite's +3.5% change, with a Zacks Rank 3 (Hold), suggesting that ABT is expected to mirror the overall market performance in the near future [9].

Core Insights - Everest Group, Ltd. (EG) is valued at a market cap of $15.1 billion and operates as a leading global reinsurance and insurance provider, offering a wide range of products across various regions [1] Financial Performance - EG is expected to announce its fiscal Q3 2025 earnings results on October 29, with analysts predicting an adjusted earnings of $9.13 per share, a decrease of nearly 37.6% from $14.62 per share in the same quarter last year [2] - For fiscal 2025, analysts forecast an adjusted EPS of $45.52, representing a 52.6% increase from $29.83 in fiscal 2024 [3] Stock Performance - Over the past 52 weeks, EG stock has declined nearly 9.6%, underperforming the S&P 500 Index, which rose by 16.3%, and the Financial Select Sector SPDR Fund, which increased by 16.5% [4] - On October 9, EG shares fell by 2.3% after Wells Fargo analyst Elyse Greenspan reaffirmed a "Hold" rating with a price target of $383 [5] - The consensus among analysts is cautiously optimistic, with a "Moderate Buy" rating; among 18 analysts, five recommend "Strong Buy," two "Moderate Buy," nine suggest "Hold," and two have a "Strong Sell" rating [5] - The average analyst price target of $382.88 indicates a premium of 8.8% from current market prices [5]

Core Insights - The upcoming earnings report for Dave & Buster's (PLAY) is anticipated to show quarterly earnings of $0.88 per share, reflecting a decline of 21.4% year-over-year, while revenues are forecasted to be $561.95 million, indicating a slight increase of 0.9% compared to the previous year [1] - Over the last 30 days, the consensus EPS estimate has been revised downward by 4.6%, highlighting a collective reassessment by analysts [1][2] Revenue Estimates - Analysts project 'Entertainment revenues' to reach $376.80 million, representing a year-over-year change of +0.3% [4] - The consensus estimate for 'Food and beverage revenues' is $185.10 million, indicating a +2% change from the same quarter last year [4] Store Count and Market Performance - The estimated 'Stores Count - End of Period' is expected to be 237, up from 224 in the previous year [4] - Dave & Buster's shares have decreased by 13.9% over the past month, contrasting with the Zacks S&P 500 composite's increase of 1.9% [4]

Core Insights - Analysts project Royalty Pharma (RPRX) will report quarterly earnings of $1.10 per share, reflecting a 14.6% year-over-year increase [1] - Revenue is expected to reach $686.22 million, marking a 12.9% increase from the same quarter last year [1] - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a reevaluation of initial estimates by analysts [1] Revenue Estimates - 'Portfolio Receipts- Royalty Receipts- Products- Cystic fibrosis franchise' is projected to reach $206.12 million, a 5.8% increase year-over-year [4] - 'Portfolio Receipts- Royalty Receipts- Products- Tysabri' is estimated at $53.90 million, indicating a 15.6% decrease from the prior year [4] - 'Portfolio Receipts- Royalty Receipts- Products- Imbruvica' is expected to be $39.81 million, reflecting a 19% decrease year-over-year [5] - 'Portfolio Receipts- Royalty Receipts- Products- Xtandi' is forecasted at $42.75 million, a 10.7% increase year-over-year [5] - 'Portfolio Receipts- Royalty Receipts- Products- Promacta' is anticipated to reach $39.51 million, showing a 29.5% increase from the previous year [5] Additional Product Estimates - 'Portfolio Receipts- Royalty Receipts- Products- Cabometyx/Cometriq' is projected at $19.64 million, a 17.3% increase year-over-year [6] - 'Portfolio Receipts- Royalty Receipts- Products- Evrysdi' is expected to be $31.21 million, indicating a 25.2% increase from the prior year [6] - 'Portfolio Receipts- Royalty Receipts- Products- Trodelvy' is forecasted at $10.87 million, reflecting a 4.6% increase year-over-year [7] - 'Portfolio Receipts- Royalty Receipts- Products- Trelegy' is estimated at $57.04 million, indicating a 17.6% increase year-over-year [7] - 'Portfolio Receipts- Royalty Receipts- Products- Tremfya' is projected to reach $38.47 million, reflecting a 28.6% increase year-over-year [8] Stock Performance - Shares of Royalty Pharma have increased by 6.4% in the past month, outperforming the Zacks S&P 500 composite, which moved up by 1% [8] - The company holds a Zacks Rank 3 (Hold), suggesting it is expected to mirror overall market performance in the near future [8]

Core Viewpoint - Analysts forecast a significant decline in Suncor Energy's quarterly earnings and revenues, indicating potential challenges for the company in the upcoming earnings release [1]. Earnings Estimates - Suncor Energy is expected to report earnings of $0.50 per share, reflecting a year-over-year decline of 46.2% [1]. - Revenue is anticipated to be $7.65 billion, which represents a decrease of 19.7% compared to the same quarter last year [1]. - Over the past 30 days, the consensus EPS estimate has been revised downward by 0.8%, indicating a collective reassessment by analysts [2]. Key Metrics Forecast - Total refined product sales per day are projected to reach 493.77 thousand barrels, down from 594.70 thousand barrels in the same quarter last year [5]. - Sales volumes per day for total Oil Sands operations are expected to be 730.66 thousand barrels, slightly up from 726.40 thousand barrels year-over-year [5]. - Crude oil processed per day in Eastern North America is forecasted at 202.02 thousand barrels, compared to 169.80 thousand barrels in the same quarter last year [6]. - Crude oil processed per day in Western North America is estimated at 195.20 thousand barrels, also up from 169.80 thousand barrels year-over-year [6]. - The total crude oil processed per day is expected to be 397.22 thousand barrels, down from 430.00 thousand barrels in the previous year [7]. - Production volumes per day for Oil Sands operations (non-upgraded bitumen) are projected at 265.67 thousand barrels, compared to 254.30 thousand barrels last year [7]. - Production volumes per day for Oil Sands operations (upgraded) are expected to reach 464.99 thousand barrels, slightly up from 461.70 thousand barrels year-over-year [8]. - Sales volumes per day for Oil Sands operations (upgraded) are also forecasted at 464.99 thousand barrels, compared to 453.80 thousand barrels last year [9]. - Production volumes per day for total Fort Hills bitumen production are estimated at 157.14 thousand barrels, down from 166.90 thousand barrels year-over-year [11]. - Production volumes per day for total Syncrude production are projected at 212.74 thousand barrels, up from 171.10 thousand barrels last year [11]. - Production volumes per day for E&P Canada are expected to be 47.50 thousand barrels, down from 49.00 thousand barrels year-over-year [12]. Market Performance - Suncor Energy shares have shown a return of +1.8% over the past month, outperforming the Zacks S&P 500 composite, which increased by +0.6% [12].